- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.08. | Incannex receives final A$5.1m R&D tax incentive refund | 2 | Investing.com | ||
| 11.08. | Incannex Healthcare Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.07. | Incannex Healthcare: Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea | 268 | GlobeNewswire (Europe) | First clinical sites approved and actively screening potential participantsRepresents another major milestone in the advancement of IHL-42X towards Phase III developmentIHL-42X has received FDA Fast... ► Artikel lesen | |
| 23.07. | Incannex Healthcare Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.06. | Incannex receives U.S. patent for sleep apnea drug IHL-42X | 2 | Investing.com | ||
| 25.06. | Incannex Healthcare: Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea | 595 | GlobeNewswire (Europe) | MELBOURNE, Australia and NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative... ► Artikel lesen | |
| 25.06. | Incannex Healthcare Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.06. | Incannex Healthcare: Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility | 492 | GlobeNewswire (Europe) | NEW YORK and MELBOURNE, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative... ► Artikel lesen | |
| INCANNEX HEALTHCARE Aktie jetzt für 0€ handeln | |||||
| 09.06. | Incannex Healthcare: Incannex Announces Initiation of Research Coverage by Alliance Global Partners | 340 | GlobeNewswire (Europe) | MELBOURNE, Australia and NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative... ► Artikel lesen | |
| 09.06. | Incannex Healthcare Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.05. | Incannex Healthcare Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.05. | Incannex launches DReAMzz study for sleep apnea treatment | 2 | Investing.com | ||
| 14.05. | Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea | 610 | GlobeNewswire (Europe) | MELBOURNE, Australia and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for... ► Artikel lesen | |
| 12.05. | Incannex Healthcare Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.04. | Incannex begrüßt US-Erlass zur Beschleunigung von Therapien für psychische Erkrankungen | 1 | Investing.com Deutsch | ||
| 22.04. | Incannex supports White House order on mental health treatments | 4 | Investing.com | ||
| 22.04. | Incannex Healthcare Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.03. | Incannex reaktiviert Aktienrückkaufprogramm nach Phase der Inaktivität | 2 | Investing.com Deutsch | ||
| 27.03. | Incannex resumes share buyback after period of inactivity | 1 | Investing.com | ||
| 27.03. | Incannex Healthcare: Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 13,420 | -1,68 % | Eckert & Ziegler: Warum der höhere Gewinn zählt | ||
| MCKESSON | 739,00 | +0,35 % | McKesson Corp. Reveals Fall In Q1 Bottom Line | WASHINGTON (dpa-AFX) - McKesson Corp. (MCK) reported earnings for first quarter that Drops, from last yearThe company's earnings totaled $614 million, or $5.17 per share. This compares with... ► Artikel lesen | |
| HEALWELL AI | 0,480 | -2,34 % | HEALWELL AI: HEALWELL AI's DARWEN AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation | Pentavere advances from winning the 2024 Prix Galien USA Award to competing internationally among Prix Galien winners from around the world, further validating DARWEN AI as a globally recognized... ► Artikel lesen | |
| LIFEWARD | 7,420 | +1,37 % | H.C. Wainwright reiterates Lifeward stock rating on revenue growth | ||
| SENSEONICS | 8,250 | -0,60 % | Senseonics sees activist investor take a major stake | ||
| IMUNON | 1,430 | +2,88 % | Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer | Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,868 | +1,49 % | BMO initiates Perspective Therapeutics stock at Outperform, $11 target | ||
| INSPIREMD | 0,760 | +4,11 % | InspireMD Targets $9 Million Of Annual Cost Savings As CGuard TCAR Study Reports 100% Acute Device Success | ||
| MYOMO | 1,488 | +0,13 % | Myomo expects $45M-$47M full-year revenue while targeting second-half cash burn below $2M | ||
| GT BIOPHARMA | 0,289 | 0,00 % | GT Biopharma, Inc.: GT Biopharma Reports Second Quarter 2026 Financial Results | Phase 1 trial evaluating GTB-3650 TriKE- remains ongoing, with an update anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE- in multiple solid tumor types known to express B7-H3... ► Artikel lesen | |
| INOGEN | 4,860 | +0,83 % | Inogen (INGN) Cuts Guidance Even As Profitability Climbs | ||
| INTELLIGENT BIO SOLUTIONS | 2,530 | +0,80 % | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth | Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units Full year gross profit margin expanded to 48.63%, up 778 basis points year-over-year... ► Artikel lesen | |
| GLUCOTRACK | 0,332 | -4,43 % | Glucotrack, Inc. - 8-K, Current Report | ||
| LENSAR | 8,690 | 0,00 % | LENSAR, Inc.: LENSAR Reports First Quarter 2026 Results and Provides Business Update | 7 ALLY Robotic Cataract Laser Systems® ("ALLY System") Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026 First Quarter Recurring Revenue was $12.6 million Total Laser... ► Artikel lesen | |
| LEXARIA BIOSCIENCE | 10,990 | +0,69 % | Lexaria Bioscience erfüllt wieder Nasdaq-Anforderungen - Aktie bleibt gelistet |
Das Unternehmen INCANNEX HEALTHCARE INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 3,550 Euro und damit -0,56 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INCANNEX HEALTHCARE INC finden Sie auf Wallstreet Online.